KNE — Kane Biotech Income Statement
0.000.00%
Last trade - 00:00- CA$9.12m
- CA$10.69m
- CA$2.08m
Annual income statement for Kane Biotech, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.34 | 1.61 | 2.67 | 0.149 | 2.08 |
| Cost of Revenue | |||||
| Gross Profit | 0.527 | 0.568 | 1.41 | 0.109 | 0.872 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 5.57 | 6.49 | 6.03 | 3.51 | 6 |
| Operating Profit | -4.22 | -4.88 | -3.36 | -3.36 | -3.92 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.85 | -4.85 | -3.82 | -4.56 | -4.47 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.85 | -4.85 | -3.82 | -4.56 | -3.16 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -3.85 | -4.6 | -3.89 | -5.03 | 6.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.85 | -4.6 | -3.89 | -5.03 | 6.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.036 | -0.041 | -0.032 | -0.036 | -0.024 |